Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. - Wikidata - wikimedia - TriplyDB

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

http://www.wikidata.org/entity/Q33756818

about

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer Siltuximab (CNTO 328): a promising option for human malignancies Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration Microenvironmental regulation of therapeutic response in cancer Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention?Paraneoplastic thrombocytosis in gastrointestinal cancer.Role of interleukin-6 in cancer progression and therapeutic resistance.Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells.DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.The role of STAT3 in leading the crosstalk between human cancers and the immune system.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Secretion of an immunoreactive single-chain variable fragment antibody against mouse interleukin 6 by Lactococcus lactis.Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma.

P2860

Q26769917-B60D4CEE-28E5-4B5F-8D11-16B4AC830BEA Q28082572-56368BA7-3F42-4D01-B038-3A1A8FFABE9D Q30660919-993CFA2A-1689-49B7-9EFC-1CC05FA72D50 Q33654609-45427481-3B93-4D05-944B-3B7B0B823B9A Q35631966-A4192FA1-02AA-4536-9CC3-26165B43ACD4 Q35958155-CB426B9B-5597-4880-BE5B-557A55FB6FC0 Q36238664-E8C24D82-6FD9-43D1-B7C3-0F8624593813 Q36356086-A16F7118-FF3D-4C55-BABA-4672D1B63415 Q36916291-56EB569A-B2D9-48FF-B2BC-633F97DB80C5 Q36963605-51A43BF2-39AD-41A6-B70D-77364E0378DF Q38328376-F2CE29EC-FAF9-4ED2-8356-0E32EEB00A84 Q38823142-EB46D5FF-CAA7-41CD-8DAE-8677C3968AFA Q38853625-C12423AC-DA28-4313-862A-C4E081604147 Q38925157-4F7FFEC8-A828-4238-AAB1-3A1BE4C42061 Q39084627-C2954B4D-B1AE-460E-A60D-99E9EB19A7FA Q42013055-C730FD3C-DCC8-4CB1-892D-5A9CE543B585 Q48370424-17A7A674-6AEA-4D88-BECF-1A62E6FEC93C Q49389245-67D1C56E-BD25-482B-8761-1E1655930337 Q49990319-647783EC-842E-4449-B29E-615A843868CA Q50191433-0370A6F1-A2F2-4DED-B907-087D30574228 Q51141275-D61F43EA-0E36-4CA9-A2A3-EF53B30DD096 Q52336242-29FA43EF-5AFE-46A6-BB0D-C7EACFB2337D Q52560420-A80833AC-B1CD-4539-93F9-8E1640518873 Q52895606-6126F5D3-8C25-4AC7-BAEC-923A583C2F73

P2860

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

http://www.wikidata.org/entity/Q33756818

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antitumor efficacy of the anti ...... nograft models of lung cancer.

@ast

Antitumor efficacy of the anti ...... nograft models of lung cancer.

@en

type

label

Antitumor efficacy of the anti ...... nograft models of lung cancer.

@ast

Antitumor efficacy of the anti ...... nograft models of lung cancer.

@en

prefLabel

Antitumor efficacy of the anti ...... nograft models of lung cancer.

@ast

Antitumor efficacy of the anti ...... nograft models of lung cancer.

@en

P1433

Q33756818-FAAC0E00-1DA8-47AB-A53D-0FD57BECDBEE

P1476

Q33756818-AD90E431-85E6-485A-BFAC-6460F7BE479B

P2093

Q33756818-1D5BB53E-EA93-4E59-A82F-5945DC3A0F21

Q33756818-49A2186A-1731-4052-9B65-136A81FCB3CF

Q33756818-6A609C30-B4F5-42FF-B28A-5823030FDF94

Q33756818-A542B036-CB16-4CD5-B773-E7240A251E8B

Q33756818-AA438DEE-1EC7-477A-8037-9C7614F210F0

Q33756818-E066D6B3-76AC-4C43-977C-2E54797F7D7D

Q33756818-F0223FF5-1375-479D-9354-71B269DE3F03

P2860

Q33756818-06DBB1CF-595D-43FD-B731-144C5745347E

Q33756818-08C302A8-9C73-4A26-9EE0-085D709A339D

Q33756818-133E84CB-AC50-4E6C-8CA4-B8A86EC3C48B

Q33756818-1F91E580-3F4A-4785-B451-FAD59881F8D4

Q33756818-3E3AAEB7-F594-4FA6-B3B0-8C0B93892B93

Q33756818-411B6093-FCA0-4C34-B253-6AFA1F393FDA

Q33756818-4AB4F19F-A11D-4CEF-9CA0-67125D761078

Q33756818-50931D8F-673C-4BBC-AC34-EDB9F25B4A78

Q33756818-612ADB8D-D5C7-4EB0-A289-BD797411A53A

Q33756818-69AE9B79-5708-462E-B3B4-373ED9B77EB2

P304

Q33756818-01BF36AF-D39D-4A7E-ABAF-90E03B7B6D36

P31

Q33756818-2F74B86F-63DE-41E4-818E-4F11973F8176

P356

Q33756818-0D8116D9-8EC2-4F86-AD2E-9681B791CABC

P433

Q33756818-FDF87E34-4569-4971-9806-129EBE05A70D

P478

Q33756818-8C885F37-1CBB-4D0E-8925-F0A0785FF861

P577

Q33756818-D62921D1-3594-48FB-AE52-B0405574337A

P698

Q33756818-DDAF9352-061B-449D-970C-3AAD46CD59EB

P921

Q33756818-93CCD2C3-6447-4917-B91F-51DB4B86AADF

P932

Q33756818-6BB1FA22-84AF-4671-901D-6412DBBB0D28

P356

JTO.0000000000000193

P1433

Journal of Thoracic Oncology

P1476

Antitumor efficacy of the anti ...... nograft models of lung cancer.

@en

P2093

Eric B Haura

http://www.w3.org/2001/XMLSchema#string

Kate Sasser

http://www.w3.org/2001/XMLSchema#string

Lanxi Song

http://www.w3.org/2001/XMLSchema#string

Matthew A Smith

http://www.w3.org/2001/XMLSchema#string

Parul Doshi

http://www.w3.org/2001/XMLSchema#string

Soner Altiok

http://www.w3.org/2001/XMLSchema#string

William Fulp

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Comprehensive genomic characterization of squamous cell lung cancers.

Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation

The STATs of cancer--new molecular targets come of age

Stat3 as an oncogene

Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein.

Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression

P304

974-982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0000000000000193

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24922005

http://www.w3.org/2001/XMLSchema#string

P921

P932

4057975

http://www.w3.org/2001/XMLSchema#string